Valuation: Ipsen

Market Cap 12.78B 14.66B 12.07B 10.96B 20.53B 1,407B 20.62B 145B 55.79B 715B 55.06B 53.84B 2,301B P/E 2026 *
13x
P/E 2027 * 13.3x
Enterprise Value 11.54B 13.24B 10.9B 9.9B 18.55B 1,270B 18.62B 131B 50.39B 646B 49.73B 48.63B 2,078B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.26x
Free-Float
40.65%
Yield 2026 *
0.98%
Yield 2027 * 0.98%
1 day+0.55%
1 week-0.95%
Current month-4.40%
1 month-4.93%
3 months+1.56%
6 months-0.89%
Current year+31.68%
1 week 154.1
Extreme 154.1
160.9
1 month 154.1
Extreme 154.1
170.3
Current year 116
Extreme 116
176.6
1 year 109
Extreme 109
176.6
3 years 88.05
Extreme 88.05
176.6
5 years 77.28
Extreme 77.28
176.6
10 years 35.52
Extreme 35.52
176.6
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2020
Chief Executive Officer 57 31/12/2019
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 29/08/2005
Chairman 68 21/11/2010
Director/Board Member 69 31/05/2012
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%-0.95% - - 14.66B
+0.04%+3.34%+51.12%+101.82% 1,028B
-0.09%+1.66%+55.02%+66.18% 651B
-0.02%+2.66%+18.91%+71.47% 466B
-1.22%+3.66%+36.44%+38.32% 346B
-0.79%+2.73%+19.03%+25.08% 266B
+0.58%+6.76%+11.13%+16.52% 259B
+1.55%+2.20%+39.81%+46.55% 208B
+0.79%+1.84%-28.27%-56.71% 191B
-0.52%+4.45%+32.12%+98.51% 186B
Average +0.24%+3.26%+26.15%+45.30% 400.19B
Weighted average by Cap. +0.23%+3.09%+35.15%+61.76%

Financials

2026 *2027 *
Net sales 4.54B 5.21B 4.29B 3.9B 7.3B 500B 7.33B 51.39B 19.83B 254B 19.57B 19.14B 818B 4.64B 5.32B 4.38B 3.98B 7.45B 510B 7.48B 52.45B 20.24B 259B 19.98B 19.53B 835B
Net income 1.01B 1.16B 954M 867M 1.62B 111B 1.63B 11.43B 4.41B 56.54B 4.35B 4.26B 182B 985M 1.13B 930M 845M 1.58B 108B 1.59B 11.15B 4.3B 55.13B 4.24B 4.15B 177B
Net Debt -1.24B -1.42B -1.17B -1.06B -1.99B -136B -2B -14B -5.4B -69.26B -5.33B -5.21B -223B -2.3B -2.64B -2.17B -1.97B -3.69B -253B -3.71B -26.01B -10.04B -129B -9.91B -9.69B -414B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
18/09/26 €155.90 +0.45% 6,781
17/09/26 €155.20 -2.76% 25,993
16/09/26 €159.60 -0.81% 125,208
15/09/26 €160.90 +1.64% 67
14/09/26 €158.30 +0.32% 147
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
155.90EUR
Average target price
166.07EUR
Spread / Average Target
+6.52%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!